Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.11.19.20234153: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The hospital institutional review boards approved this study as minimal risk and waived informed consent requirements.
Consent: The hospital institutional review boards approved this study as minimal risk and waived informed consent requirements.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in …SciScore for 10.1101/2020.11.19.20234153: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The hospital institutional review boards approved this study as minimal risk and waived informed consent requirements.
Consent: The hospital institutional review boards approved this study as minimal risk and waived informed consent requirements.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has limitations. The time-dependent propensity score methodology produced matched sets in which patients were very similar on measured confounders. However, there could be unmeasured variables that biased our treatment effect estimates. It is possible there was a secular trend in the quality of COVID-19 patient care as our health system gained experience, so we limited our matched control group to the time period when remdesivir was available. We required controls to remain hospitalized for the period of time remdesivir patients were on treatment, not exceeding 5 days. This was a pre-analysis design to avoid bias from matching controls with different disease severity that would not be controlled for by the measurement confounders. However, our findings are sensitive to this restriction being reduced to 3 or fewer days. This is consistent with the ACTT-1 trial that excluded patients expected to be discharged within 3 days of randomization.8 We also took into account the increased use of dexamethasone after the RECOVERY trial.16 Removing patients who received remdesivir plus dexamethasone (or corticosteroids in general) did not appreciably change the overall findings. In conclusion, remdesivir use in patients who met the EUA criteria led to a significant decrease in the time to clinical recovery in patients admitted to the hospital for COVID-19. These results provide further evidence that remdesivir is effective in reducing the duration of COVID-19 illness, that a 5-d...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
